Business
Fangzhou Raises HK$150 Million in Share Placement to Accelerate AI-Powered Chronic Care Platform
HONG KONG, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, has successfully completed a HK$150 million share placement, strengthening its balance sheet to accelerate investment in artificial intelligence and platform upgrades. The shares were priced at HK$3.32 per share, with the shares placed representing approximately 3.26% of the Company’s enlarged issued share capital following complet
About this update from Fangzhou Inc.
[{"type":"image","alt":"Fangzhou Inc.","displaySize":"","headline":null,"caption":"Fangzhou Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":95,"url":"https://media.zenfs.com/en/globenewswire.com/912b0b077ef808f302b710d614115ef6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3I4M1onr9I9LGQ_MtZRvAw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/912b0b077ef808f302b710d614115ef6","width":300,"height":95}},"lazy":false},{"type":"text","content":"HONG KONG, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, has successfully completed a HK$150 million share placement, strengthening its balance sheet to accelerate investment in artificial intelligence and platform upgrades.","length":334,"tagName":"p"},{"type":"text","content":"The shares were priced at HK$3.32 per share, with the shares placed representing approximately 3.26% of the Company’s enlarged issued share capital following completion of the subscription.","length":189,"tagName":"p"},{"type":"text","content":"Fangzhou plans to allocate approximately 90% of the net proceeds after deducting related costs and expenses to accelerate development of the Company's AI-driven chronic disease management platform. This encompasses model development and optimization, infrastructure and computational resource expansion, talent recruitment across AI and clinical specialties, data collection and annotation and knowledge base development, and roll-out and marketing of AI-enhanced services to capture underserved patient and physician populations.","length":534,"tagName":"p"},{"type":"text","content":"The fundraising comes amid renewed momentum in medical AI at the start of the year, as global and domestic technology players accelerate development of LLMs focused on healthcare. Fangzhou announced the completion of a major upgrade of its “AI + H2H (Hospital-to-Home)” ecosystem in 2025, embedding AI across the full chronic disease management value chain to support continuous patient care while improving the efficiency of medical resource allocation.","length":454,"tagName":"p"},{"type":"text","content":"With an early-mover advantage in AI-enabled chronic care, Fangzhou has drawn increasing attention from institutional in...